marketcaparena
Search

    BIAF

    bioAffinity Technologies, Inc.

    Company overview

    Market capitalization
    $60.03M
    Employees
    57
    Latest publication
    2026-09-29
    About bioAffinity Technologies, Inc.

    bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue1,351,527USD1,592,813USD1,446,066USD1,269,483USD1,853,597USD2,207,593USD2,350,386USD2,397,652USD
    Cost Of Revenue1,043,153USD1,291,602USD1,055,571USD1,016,602USD1,367,860USD1,715,798USD1,440,158USD1,407,710USD
    Gross Profit308,373USD301,211USD390,495USD252,881USD485,737USD491,795USD910,228USD989,942USD
    Research Development349,707USD668,813USD473,900USD440,651USD505,739USD518,186USD368,202USD453,895USD
    Selling General Administrative3,241,602USD3,037,178USD2,209,441USD2,214,561USD2,452,549USD251,948USD2,364,592USD251,948USD
    Total Operating Expenses3,925,349USD3,438,174USD2,683,341USD2,768,441USD3,112,876USD3,438,348USD2,884,092USD3,077,740USD
    Operating Income-3,616,976USD-3,136,963USD-2,292,846USD-2,515,560USD-2,627,139USD-2,946,553USD-1,973,864USD-2,087,798USD
    Interest Income10,026USD19,730USD1,088USD2,025USD542USD4,069USD2,228USD5,186USD
    Interest Expense14,722USD13,069USD5,358USD10,460USD15,485USD25,045USD21,631USD22,249USD
    Net Interest Income-4,696USD6,661USD-4,270USD-8,435USD-14,943USD-20,976USD-19,403USD-17,063USD
    Income Before Tax-3,630,610USD-3,134,285USD-5,047,902USD-4,031,803USD-2,651,722USD-2,966,897USD-1,998,281USD-2,104,860USD
    Tax Provision0USD3,181USD3,182USD28,984USD8,695USD0USD2,559USD5,419USD
    Net Income-3,630,610USD-3,137,466USD-5,051,084USD-4,060,787USD-2,660,417USD-2,966,897USD-2,000,840USD-2,110,279USD
    Net Income From Continuing Ops-3,630,610USD-3,137,466USD-5,051,084USD-4,060,787USD-2,660,417USD-2,966,897USD-2,000,840USD-2,110,279USD
    Ebit-3,616,976USD-3,136,963USD-5,042,544USD-4,021,343USD-2,636,237USD-2,941,854USD-1,976,650USD-2,082,611USD
    Ebitda-3,502,458USD-3,013,304USD-4,929,184USD-3,908,114USD-2,481,649USD-2,788,222USD-1,825,352USD-1,931,541USD
    Depreciation And Amortization114,518USD123,659USD113,360USD113,229USD154,588USD153,632USD151,298USD151,070USD
    Reconciled Depreciation114,518USD123,659USD113,360USD113,229USD154,588USD153,632USD151,298USD151,070USD
    Total Other Income Expense Net-13,634USD2,678USD-2,755,056USD-1,516,243USD-24,583USD-20,344USD-24,417USD-17,062USD
    Income Tax Expense—3,181USD3,182USD28,984USD8,695USD-23,300USD2,559USD5,419USD
    Selling And Marketing Expenses—————2,221,000USD—2,221,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USD
    Total Revenue6,161,959USD9,362,000USD2,532,000USD4,803USD1,306USD0USD—
    Cost Of Revenue4,731,635USD5,983,000USD1,741,000USD467USD4,817USD22,242USD40,278USD
    Gross Profit1,430,324USD3,379,000USD791,615USD4,336USD-4,817USD-22,242USD-40,278USD
    Research Development2,089,103USD1,783,000USD1,725,000USD1,524,170USD1,137,951USD1,610,042USD1,852,589USD
    Selling General Administrative9,913,729USD9,943,473USD6,790,654USD2,727,000USD880,772USD994,343USD—
    Total Operating Expenses12,002,832USD12,332,000USD8,765,000USD4,015,394USD2,202,005USD2,582,143USD3,051,964USD
    Operating Income-10,572,508USD-8,953,000USD-7,973,000USD-4,011,058USD-2,206,822USD-2,604,385USD-3,092,242USD
    Interest Income23,385USD17,610USD148,418USD46,708USD424USD1,073USD—
    Interest Expense44,372USD92,475USD37,125USD2,533,000USD1,002,000USD382,171USD214,834USD
    Net Interest Income-20,987USD-74,865USD47,327USD-2,485,932USD-1,001,430USD-381,098USD—
    Income Before Tax-14,865,712USD-9,028,350USD-7,916,000USD-8,151,654USD-6,324,463USD-7,265,987USD-3,304,299USD
    Income Tax Expense44,042USD11,650USD20,993USD2,459USD1,950USD2,750USD3,200USD
    Tax Provision44,042USD11,650USD18,699USD2,459USD1,950USD2,750USD—
    Net Income-14,909,754USD-9,040,000USD-7,937,000USD-8,154,113USD-6,326,413USD-7,268,737USD-3,307,499USD
    Net Income From Continuing Ops-14,909,754USD-9,039,831USD-7,238,430USD-8,154,113USD-6,326,413USD-7,268,737USD—
    Ebit-10,572,508USD-8,935,637USD-7,878,592USD-5,619,014USD-5,322,609USD-6,883,815USD-3,089,465USD
    Ebitda-10,067,673USD-8,330,000USD-7,629,000USD-5,608,832USD-5,317,792USD-6,861,573USD-3,049,187USD
    Depreciation And Amortization504,835USD605,637USD249,592USD10,182USD4,817USD22,242USD40,278USD
    Reconciled Depreciation504,836USD605,637USD108,135USD10,182USD4,817USD22,242USD—
    Total Other Income Expense Net-4,293,204USD-75,350USD57,210USD-4,140,596USD-4,117,641USD-4,661,602USD-212,057USD
    Selling And Marketing Expenses————188,099USD——
    Net Income Applicable To Common Shares————-6,326,413USD-7,268,737USD—
    Unclassified Operating Expenses——————1,199,375USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Assets7,945,252USD10,960,772USD11,546,369USD4,751,075USD5,547,283USD6,513,667USD6,552,014USD6,656,448USD
    Intangible Assets702,222USD716,806USD731,389USD745,972USD760,556USD775,139USD789,722USD804,306USD
    Other Current Assets479,913USD519,916USD460,187USD400,151USD416,550USD422,995USD440,027USD253,726USD
    Total Liab4,283,866USD3,683,116USD2,644,171USD6,887,183USD4,107,879USD3,911,631USD3,430,989USD3,223,334USD
    Total Stockholder Equity3,661,386USD7,277,656USD8,902,198USD-2,136,108USD1,439,404USD2,602,036USD3,121,025USD3,433,114USD
    Other Current Liab2,033,924USD1,717,989USD984,547USD1,048,034USD1,370,735USD1,398,722USD904,252USD490,241USD
    Common Stock31,464USD31,461USD24,264USD197,236USD124,777USD106,593USD90,064USD79,407USD
    Capital Stock31,465USD31,462USD24,265USD197,236USD124,777USD106,593USD90,064USD79,407USD
    Retained Earnings-72,184,674USD-68,554,064USD-65,416,598USD-60,365,514USD-56,304,727USD-53,644,310USD-50,677,413USD-48,676,573USD
    Good Will1,404,486USD1,404,486USD1,404,486USD1,404,486USD1,404,486USD1,404,486USD1,404,486USD1,404,486USD
    Cash3,098,366USD6,449,782USD7,669,195USD802,835USD444,706USD1,105,291USD756,580USD801,311USD
    Cash And Short Term Investments3,098,366USD6,449,782USD7,669,195USD802,835USD444,706USD1,105,291USD756,580USD801,311USD
    Total Current Assets4,341,401USD7,565,208USD8,613,606USD1,668,826USD1,863,782USD2,695,098USD2,549,138USD2,680,431USD
    Total Current Liabilities3,184,960USD2,906,166USD2,359,573USD2,588,304USD3,415,409USD3,104,905USD2,491,164USD2,326,288USD
    Current Deferred Revenue31,140USD42,405USD37,915USD24,404USD24,404USD24,404USD24,404USD26,135USD
    Net Debt-1,715,775USD-5,288,961USD-6,988,247USD-132,838USD886,456USD395,903USD962,816USD1,057,545USD
    Short Term Debt283,685USD383,871USD396,350USD346,029USD638,692USD694,468USD779,571USD961,810USD
    Short Long Term Debt61,141USD105,161USD136,396USD32,946USD104,766USD171,669USD267,081USD4,106USD
    Short Long Term Debt Total1,382,591USD1,160,821USD680,948USD669,997USD1,331,162USD1,501,194USD1,719,396USD1,858,856USD
    Long Term Debt38,915USD41,313USD43,658USD45,952USD48,156USD20,180USD21,679USD22,766USD
    Net Receivables685,235USD541,962USD448,990USD421,869USD963,744USD1,139,204USD1,327,168USD1,595,626USD
    Inventory77,887USD53,548USD35,234USD43,971USD38,782USD27,608USD25,363USD29,768USD
    Accounts Payable836,211USD761,901USD940,761USD1,169,837USD1,381,578USD987,311USD782,937USD848,102USD
    Property Plant Equipment Net1,484,327USD1,261,457USD784,073USD918,977USD1,498,784USD1,619,268USD1,788,992USD1,747,550USD
    Property Plant Equipment Gross2,788,859USD1,965,703USD1,902,267USD1,940,758USD2,688,335USD2,155,519USD2,699,491USD2,200,524USD
    Common Stock Shares Outstanding4,494,752shares1,721,082shares1,066,350shares800,718shares541,900shares413,067shares413,067shares379,633shares
    Non Current Assets Total3,603,851USD3,395,564USD2,932,763USD3,082,249USD3,683,501USD3,818,569USD4,002,876USD3,976,017USD
    Non Current Liabilities Total1,098,906USD776,950USD284,598USD4,298,879USD692,470USD806,726USD939,825USD897,046USD
    Non Currrent Assets Other12,816USD12,815USD12,815USD12,814USD19,675USD19,676USD19,676USD19,675USD
    Net Working Capital1,156,441USD4,659,042USD6,254,033USD-919,478USD-1,551,627USD-409,807USD57,974USD354,143USD
    Unclassified Non Current Liabilities1,059,991USD——4,252,927USD————
    Unclassified Equity75,783,131USD75,768,797USD74,270,267USD57,834,934USD57,494,577USD56,033,160USD53,618,310USD51,950,873USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USD
    Total Assets10,960,772USD6,513,667USD8,221,552USD12,182,125USD1,453,308USD145,605USD658,810USD
    Intangible Assets716,806USD775,139USD833,472USD————
    Other Current Assets519,916USD422,995USD321,017USD531,899USD76,065USD5,665USD37,493USD
    Total Liab3,683,116USD3,911,631USD3,366,297USD1,138,682USD17,244,027USD15,218,468USD4,694,350USD
    Total Stockholder Equity7,277,656USD2,602,036USD4,855,255USD11,043,443USD-15,790,719USD-15,072,863USD-4,035,540USD
    Other Current Liab1,717,989USD1,398,722USD1,149,811USD541,894USD1,604,893USD976,102USD579,927USD
    Common Stock31,461USD106,593USD65,762USD58,669USD18,740USD18,724USD18,724USD
    Capital Stock31,462USD106,593USD65,762USD58,669USD18,740USD18,724USD—
    Retained Earnings-68,554,064USD-53,644,310USD-44,604,479USD-36,667,468USD-28,513,355USD-22,186,942USD-14,918,205USD
    Good Will1,404,486USD1,404,486USD1,404,486USD0USD———
    Cash6,449,782USD1,105,291USD2,821,570USD11,413,759USD1,360,638USD83,108USD578,483USD
    Cash And Short Term Investments6,449,782USD1,105,291USD2,821,570USD11,413,759USD1,360,638USD83,108USD578,483USD
    Total Current Assets7,565,208USD2,695,098USD3,972,745USD11,961,687USD1,438,233USD118,655USD617,506USD
    Total Current Liabilities2,906,166USD3,104,905USD2,247,829USD1,138,682USD13,039,525USD11,120,684USD4,694,350USD
    Current Deferred Revenue42,405USD24,404USD33,058USD————
    Net Debt-5,288,961USD395,903USD-1,242,931USD-11,162,013USD10,003,771USD9,923,553USD3,432,522USD
    Short Term Debt383,871USD694,468USD460,171USD251,746USD11,204,225USD9,953,195USD4,011,005USD
    Short Long Term Debt105,161USD171,669USD—251,746USD11,204,225USD9,953,195USD—
    Short Long Term Debt Total1,160,821USD1,501,194USD1,578,639USD251,746USD11,364,409USD10,006,661USD4,011,005USD
    Long Term Debt41,313USD20,180USD——160,184USD53,466USD—
    Net Receivables541,962USD1,139,204USD811,674USD10,489USD1,530USD1,530USD1,530USD
    Inventory53,548USD27,608USD18,484USD5,540USD71,846USD28,352USD—
    Accounts Payable761,901USD987,311USD604,789USD345,042USD230,407USD191,387USD103,418USD
    Property Plant Equipment Net1,261,457USD1,619,268USD1,994,789USD214,438USD4,633USD9,450USD28,804USD
    Property Plant Equipment Gross1,965,703USD2,155,519USD2,367,912USD483,618USD263,631USD263,631USD—
    Common Stock Shares Outstanding1,721,082shares404,333shares291,600shares149,967shares90,933shares245,933shares245,933shares
    Non Current Assets Total3,395,564USD3,818,569USD4,248,807USD220,438USD15,075USD26,950USD41,304USD
    Non Current Liabilities Total776,950USD806,726USD1,118,468USD596,788USD4,204,502USD4,097,784USD—
    Non Currrent Assets Other12,815USD19,676USD16,060USD6,000USD10,442USD17,500USD12,500USD
    Net Working Capital4,659,042USD-409,807USD1,724,916USD10,823,005USD-11,593,350USD-11,002,029USD—
    Unclassified Equity75,768,797USD56,033,160USD49,328,210USD47,593,573USD16,729,473USD11,120,948USD10,882,664USD
    Unclassified Non Current Liabilities——1,118,468USD—4,036,376USD4,044,318USD—
    Deferred Long Term Liab————7,942USD——
    Other Assets————10,442USD17,500USD—
    Accumulated Other Comprehensive Income————-4,044,317USD-4,044,317USD-18,723USD
    Net Tangible Assets————-15,790,719USD-15,072,863USD—
    Unclassified Current Liabilities————-11,204,225USD-9,953,195USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-3,630,610USD-3,137,466USD-5,051,084USD-4,060,787USD-2,660,417USD-2,966,897USD-2,000,840USD-2,110,279USD
    Depreciation114,518USD-381,177USD113,360USD113,229USD154,588USD153,632USD151,298USD151,070USD
    Stock Based Compensation14,340USD-605,355USD67,132USD211,607USD326,616USD234,087USD471,882USD287,294USD
    Other Non Cash Items14,340USD1,770,634USD2,747,460USD1,062,818USD234,087USD—-1,008,494USD458,971USD
    Change To Account Receivables-143,274USD-690,214USD-27,121USD541,875USD175,460USD187,964USD268,458USD-472,017USD
    Change To Inventory-24,339USD7,626USD8,737USD-5,189USD-11,174USD-2,245USD4,405USD-20,281USD
    Change In Working Capital274,512USD-206,199USD-357,166USD25,927USD537,438USD902,017USD676,920USD-319,481USD
    Total Cash From Operating Activities-3,227,240USD-2,559,563USD-2,480,298USD-2,647,206USD-1,641,775USD-1,677,161USD-1,709,234USD-1,532,425USD
    Capital Expenditures-5,660USD-60,565USD-3,648USD-13,427USD-50,786USD-1USD-9,410USD-28,285USD
    Free Cash Flow-3,232,900USD-2,498,998USD-2,476,650USD-2,660,633USD-1,692,561USD-1,677,162USD-1,718,644USD-1,560,709USD
    Total Cashflows From Investing Activities-5,663USD—3,646USD-13,427USD-50,786USD—-9,410USD-28,285USD
    Net Borrowings-118,513USD-106,654USD43,125USD-166,999USD-139,193USD-187,949USD170,850USD—
    Total Cash From Financing Activities-118,513USD1,340,151USD9,343,012USD3,018,762USD1,031,976USD2,025,873USD1,673,913USD-91,144USD
    Change In Cash-3,351,416USD-1,219,413USD6,866,360USD358,129USD-660,585USD348,711USD-44,731USD-1,651,854USD
    Begin Period Cash Flow6,449,782USD7,669,195USD802,835USD444,706USD1,105,291USD756,580USD801,311USD2,453,165USD
    End Period Cash Flow3,098,366USD6,449,782USD7,669,195USD802,835USD444,706USD1,105,291USD756,580USD801,311USD
    Issuance Of Capital Stock—1,800,000USD7,463,180USD2,798,354USD0USD2,186,052USD159,833USD0USD
    Other Cashflows From Financing Activities—15,764,953USD-1,418,459USD387,407USD27,770USD27,770USD1,343,230USD495,000USD
    Unclassified Financing Cash Flow—-16,118,148USD3,255,166USD—1,143,399USD———
    Investments——3,646USD-13,427USD-50,786USD-1USD-9,410USD-28,285USD
    Sale Purchase Of Stock———————-494,853USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USD
    Net Income-14,909,754USD-9,039,831USD-7,937,011USD-8,154,113USD-6,326,413USD-7,268,737USD-3,307,499USD
    Depreciation504,835USD605,637USD249,592USD10,182USD4,817USD22,242USD40,278USD
    Stock Based Compensation671,474USD989,681USD748,823USD248,592USD43,012USD275,732USD—
    Other Non Cash Items4,481,753USD989,681USD-109,767USD3,710,291USD-244,354USD4,280,504USD455,015USD
    Change To Account Receivables597,242USD-327,530USD311,366USD-8,959USD——290USD
    Change To Inventory-25,940USD-9,124USD-12,944USD-5,540USD0USD——
    Change In Working Capital594,324USD179,718USD900,790USD114,203USD632,821USD482,620USD322,010USD
    Total Cash From Operating Activities-9,328,842USD-7,264,795USD-6,037,806USD-4,070,845USD-2,048,978USD-2,207,639USD-2,490,196USD
    Capital Expenditures-60,568USD-79,083USD-22,902USD-219,987USD0USD-2,888USD-11,404USD
    Free Cash Flow-9,389,410USD-7,343,878USD-6,060,708USD-4,290,832USD-2,048,978USD-2,210,527USD-2,501,600USD
    Total Cashflows From Investing Activities-60,568USD-79,083USD-2,209,399USD-219,987USD—-2,888USD-11,399USD
    Net Borrowings-369,721USD-169,332USD-344,984USD584,165USD3,507,258USD1,715,152USD—
    Total Cash From Financing Activities14,733,901USD5,627,599USD-344,984USD14,343,953USD3,326,508USD1,715,152USD2,335,000USD
    Issuance Of Capital Stock12,061,534USD4,350,885USD0USD6,027,414USD0USD——
    Change In Cash5,344,491USD-1,716,279USD-8,592,189USD10,053,121USD1,277,530USD-495,375USD578,483USD
    Begin Period Cash Flow1,105,291USD2,821,570USD11,413,759USD1,360,638USD83,108USD578,483USD745,078USD
    End Period Cash Flow6,449,782USD1,105,291USD2,821,570USD11,413,759USD1,360,638USD83,108USD578,483USD
    Other Cashflows From Investing Activities-60,568USD-79,083USD—————
    Other Cashflows From Financing Activities14,733,901USD1,446,046USD-2,209,399USD7,732,374USD3,114,250USD1,475,952USD2,335,000USD
    Unclassified Financing Cash Flow-11,691,813USD—2,209,399USD6,027,784USD-3,295,000USD-1,475,952USD—
    Investments—-79,083USD-2,442,828USD-219,987USD0USD-2,888USD—
    Dividends Paid———-185USD———
    Sale Purchase Of Stock———-185USD———
    Change To Liabilities————39,020USD87,969USD—
    Unclassified Operating Cash Flow————3,841,139USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductDepartment Of Defense Observational Studies1,131USD0001493152-26-022044
    Q1 2026Quarterly · 2026-03-31ProductDiagnostic Research And Development1,131USD0001493152-26-022044
    Q1 2026Quarterly · 2026-03-31ProductLaboratory Services — Health Care Patient Service1,082,210USD0001493152-26-022044
    Q1 2026Quarterly · 2026-03-31ProductLaboratory Services — Histology Service Fees250,516USD0001493152-26-022044
    Q1 2026Quarterly · 2026-03-31ProductLaboratory Services — Medical Director Fees17,461USD0001493152-26-022044
    Q1 2026Quarterly · 2026-03-31ProductLaboratory Services — Other Revenues209USD0001493152-26-022044
    FY 2025Yearly · 2025-12-31ProductDepartment Of Defense Observational Studies577USD0001493152-26-010143
    FY 2025Yearly · 2025-12-31ProductDiagnostic Research And Development577USD0001493152-26-010143
    FY 2025Yearly · 2025-12-31ProductLaboratory Services — Health Care Patient Service4,971,342USD0001493152-26-010143
    FY 2025Yearly · 2025-12-31ProductLaboratory Services — Histology Service Fees1,116,912USD0001493152-26-010143
    FY 2025Yearly · 2025-12-31ProductLaboratory Services — Medical Director Fees68,268USD0001493152-26-010143
    FY 2025Yearly · 2025-12-31ProductLaboratory Services — Other Revenues4,860USD0001493152-26-010143
    Q3 2025Quarterly · 2025-09-30ProductLaboratory Services — Health Care Patient Service1,172,948USD0001493152-25-023405
    Q3 2025Quarterly · 2025-09-30ProductLaboratory Services — Histology Service Fees255,586USD0001493152-25-023405
    Q3 2025Quarterly · 2025-09-30ProductLaboratory Services — Medical Director Fees17,274USD0001493152-25-023405
    Q3 2025Quarterly · 2025-09-30ProductLaboratory Services — Other Revenues258USD0001493152-25-023405
    Q1 2025Quarterly · 2025-03-31ProductLaboratory Services — Health Care Patient Service1,570,382USD0001493152-26-022044
    Q1 2025Quarterly · 2025-03-31ProductLaboratory Services — Histology Service Fees263,754USD0001493152-26-022044
    Q1 2025Quarterly · 2025-03-31ProductLaboratory Services — Medical Director Fees16,588USD0001493152-26-022044
    Q1 2025Quarterly · 2025-03-31ProductLaboratory Services — Other Revenues2,873USD0001493152-26-022044
    FY 2024Yearly · 2024-12-31ProductDepartment Of Defense Observational Studies8,654USD0001493152-26-010143
    FY 2024Yearly · 2024-12-31ProductDiagnostic Research And Development8,654USD0001493152-26-010143
    FY 2024Yearly · 2024-12-31ProductLaboratory Services — Health Care Patient Service8,175,670USD0001493152-26-010143
    FY 2024Yearly · 2024-12-31ProductLaboratory Services — Histology Service Fees1,103,751USD0001493152-26-010143
    FY 2024Yearly · 2024-12-31ProductLaboratory Services — Medical Director Fees66,576USD0001493152-26-010143
    FY 2024Yearly · 2024-12-31ProductLaboratory Services — Other Revenues7,371USD0001493152-26-010143
    Q3 2024Quarterly · 2024-09-30ProductDepartment Of Defense Observational Studies1,731USD0001493152-25-023405
    Q3 2024Quarterly · 2024-09-30ProductDiagnostic Research And Development1,731USD0001493152-25-023405
    Q3 2024Quarterly · 2024-09-30ProductLaboratory Services — Health Care Patient Service2,049,851USD0001493152-25-023405
    Q3 2024Quarterly · 2024-09-30ProductLaboratory Services — Histology Service Fees281,861USD0001493152-25-023405
    Q3 2024Quarterly · 2024-09-30ProductLaboratory Services — Medical Director Fees16,943USD0001493152-25-023405
    Q2 2024Quarterly · 2024-06-30ProductDiagnostic Research And Development4,038USD0001641172-25-024163
    Q2 2024Quarterly · 2024-06-30ProductLaboratory Services2,393,614USD0001641172-25-024163
    Q1 2024Quarterly · 2024-03-31ProductDepartment Of Defense Observational Studies2,885USD0001641172-25-010787
    Q1 2024Quarterly · 2024-03-31ProductDiagnostic Research And Development2,885USD0001641172-25-010787
    Q1 2024Quarterly · 2024-03-31ProductLaboratory Services — Health Care Patient Service2,149,049USD0001641172-25-010787
    Q1 2024Quarterly · 2024-03-31ProductLaboratory Services — Histology Service Fees237,972USD0001641172-25-010787
    Q1 2024Quarterly · 2024-03-31ProductLaboratory Services — Medical Director Fees16,058USD0001641172-25-010787
    Q1 2024Quarterly · 2024-03-31ProductLaboratory Services — Other Revenues427USD0001641172-25-010787
    FY 2023Yearly · 2023-12-31ProductDepartment Of Defense Observational Studies19,442USD0001641172-25-001840
    FY 2023Yearly · 2023-12-31ProductDiagnostic Research And Development19,442USD0001641172-25-001840
    FY 2023Yearly · 2023-12-31ProductLaboratory Services — Health Care Patient Service2,199,558USD0001641172-25-001840
    FY 2023Yearly · 2023-12-31ProductLaboratory Services — Histology Service Fees272,660USD0001641172-25-001840
    FY 2023Yearly · 2023-12-31ProductLaboratory Services — Medical Director Fees19,324USD0001641172-25-001840
    FY 2023Yearly · 2023-12-31ProductLaboratory Services — Other Revenues21,515USD0001641172-25-001840
    Q3 2023Quarterly · 2023-09-30ProductDefense Study4,500USD0001493152-23-040986
    Q3 2023Quarterly · 2023-09-30ProductHealth Care Other2,393USD0001493152-23-040986
    Q3 2023Quarterly · 2023-09-30ProductHealth Care Patient Service248,654USD0001493152-23-040986
    Q3 2023Quarterly · 2023-09-30ProductHistology Fees31,854USD0001493152-23-040986
    Q3 2023Quarterly · 2023-09-30ProductLaboratory Services6,158USD0001493152-23-040986
    Q3 2023Quarterly · 2023-09-30ProductRoyalty Income4,925USD0001493152-23-040986

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.